virus
must
parasit
host
cell
translat
machineri
order
make
protein
viral
progeni
studi
sought
use
signal
transduct
conduit
inhibit
multipl
kinas
influenc
translat
previou
work
indic
sever
kinas
involv
translat
includ
erk
mapk
phosphoryl
follow
rift
valley
fever
viru
rvfv
infect
furthermor
inhibit
treatment
fda
approv
drug
rapamycin
prevent
rvfv
pathogenesi
mous
model
infect
hypothes
inhibit
either
upstream
kinas
erk
mapk
would
decreas
translat
subsequ
viral
replic
treatment
inhibitor
result
decreas
phosphoryl
translat
protein
reduc
rvfv
titer
contrast
treatment
inhibitor
inhibitor
erk
inhibitor
alon
minim
influenc
rvfv
titer
combin
treatment
result
robust
inhibit
rvfv
replic
likewis
synergist
inhibit
rvfv
replic
observ
inhibitor
erk
inhibitor
combin
rapamycin
treatment
find
serv
proof
concept
regard
combin
kinas
inhibitor
treatment
rvfv
infect
rift
valley
fever
viru
rvfv
emerg
pathogen
public
health
threat
identifi
caus
agent
outbreak
viral
hemorrhag
fever
kenya
rvfv
initi
found
subsaharan
africa
sinc
discoveri
span
african
mainland
cross
madagascar
move
arabian
peninsula
footprint
rvfv
mosquito
vector
expand
combin
ubiqu
compet
mammalian
host
make
likelihood
viru
spread
global
distinct
possibl
alarm
escap
arthropodborn
virus
west
nile
viru
chikungunya
viru
zika
viru
ecolog
nich
throughout
america
give
us
potenti
harbing
futur
event
base
concern
trend
govern
public
health
author
across
globe
identifi
need
fda
approv
vaccin
treatment
rvfv
virus
encod
protein
util
host
cell
signal
pathway
meet
replic
propag
need
rvfv
limit
molecular
pathogenesi
knowledg
except
order
understand
attack
virus
therapeut
detail
understand
manipul
host
cell
machineri
essenti
previou
work
indic
sever
kinas
involv
translat
upregul
follow
rvfv
infect
specif
revers
phase
protein
array
analysi
show
phosphoryl
kinas
ribosom
kinas
extracellular
signalregul
kinas
erk
mitogenactiv
protein
kinas
mapk
increas
follow
rvfv
infect
ribosom
protein
substrat
protein
import
initi
capdepend
translat
also
phosphoryl
follow
rvfv
infect
mapk
influenc
translat
phosphoryl
mitogenactiv
protein
kinaseinteract
protein
mnk
phosphoryl
addit
upstream
regul
inhibit
mapk
treatment
result
decreas
phosphoryl
ser
mapk
intermedi
mapkactiv
kinas
activ
certain
situat
viral
infect
erk
activ
phosphoryl
thr
activ
loop
phosphoryl
promot
capdepend
translat
kinas
lever
signal
transduct
pathway
turn
modul
kinas
allow
determin
import
viral
life
cycl
entic
reason
explor
kinas
modul
follow
infect
larg
number
kinas
inhibitor
use
cancer
treatment
make
larg
potenti
armamentarium
futur
use
virus
inhibit
translat
use
fda
approv
mtor
inhibitor
rapamycin
protect
mice
rvfv
induc
pathogenesi
provid
evid
inhibit
translat
viabl
therapeut
target
inhibit
least
partial
mediat
kinas
kinas
integr
success
activ
translat
pathway
rapamycin
treatment
decreas
rvfv
n
protein
np
product
rvfv
replic
vitro
howev
rapamycin
sever
addit
effect
asid
modul
pathway
therefor
want
test
addit
inhibitor
translat
pathway
includ
direct
inhibitor
studi
abil
inhibitor
specif
inhibitor
inhibitor
erk
inhibitor
alter
rvfv
replic
hepatocyt
determin
combin
kinas
inhibitor
treatment
also
analyz
test
hypothesi
target
one
kinas
would
result
potent
inhibit
rvfv
replic
atcc
cell
maintain
dulbecco
low
glucos
modifi
minimum
essenti
medium
glutamax
nm
dexamethason
heatinactiv
fetal
bovin
serum
fb
vero
cell
atcc
manassa
va
usa
maintain
dulbecco
modifi
minimum
essenti
medium
dmem
supplement
fb
lglutamin
penicillinstreptomycin
cell
maintain
c
co
vero
cell
maintain
c
co
rvfv
vaccin
strain
viru
rescu
titer
previous
describ
viral
infect
cell
mous
hepatocyt
cell
cultur
well
plate
grown
confluenc
cell
serum
starv
h
synchron
cell
phase
cell
infect
rvfv
multipl
infect
moi
cell
incub
h
c
co
rock
cell
everi
min
infecti
media
remov
cell
wash
phosphat
buffer
salin
pb
without
ca
mg
complet
media
ad
cell
left
incub
collect
use
appropri
method
downstream
applic
specifi
time
point
protein
lysat
collect
analyz
western
blot
previous
describ
brief
primari
antibodi
cell
signal
technolog
danver
usa
kinas
cell
signal
technolog
ribosom
protein
cell
signal
technolog
cell
signal
technolog
rvfv
antibodi
ibt
bioservic
rockvil
md
usa
hrpconjug
actin
abcam
dilut
bovin
serum
albumin
tb
solut
follow
addit
appropri
secondari
antibodi
western
blot
visual
chemiluminesc
use
supersign
west
femto
maximum
sensit
substrat
kit
thermoscientif
waltham
usa
bio
rad
molecular
imag
chemidoc
xr
system
biorad
hercul
ca
usa
extracellular
supernat
collect
indic
time
point
store
c
viral
titer
determin
plaqu
assay
use
vero
cell
previous
describ
cell
plate
whitewal
plate
allow
incub
c
co
overnight
cell
treat
drug
concentr
start
micromolar
serial
dilut
drug
incub
cell
h
drug
ad
either
alon
combin
equal
concentr
per
well
need
determin
toxic
drug
drug
combin
h
cell
analyz
use
cell
titerglo
cell
luminesc
viabil
assay
promega
madison
wi
usa
accord
vendor
instruct
assay
measur
rel
atp
level
briefli
equal
volum
room
temperatur
media
cell
titerglo
reagent
ad
cell
plate
shaken
min
orbit
shaker
follow
min
room
temperatur
incub
viabil
detect
via
luminesc
detect
use
dtx
multimod
detector
beckman
coulter
brea
ca
usa
percent
viabil
calcul
rel
dmso
control
cell
plate
whitewal
plate
allow
incub
c
co
overnight
cell
pretreat
h
variou
drug
concentr
serial
dilut
drug
ad
either
alon
combin
equal
concentr
per
well
need
determin
efficaci
drug
drug
combin
cell
infect
rvfv
lack
nss
gene
replac
gene
encod
renilla
luciferas
moi
cell
incub
h
c
co
infecti
media
remov
cell
wash
pb
without
ca
mg
drug
reappli
cell
analyz
hpi
use
renillaglo
luciferas
assay
system
promega
accord
vendor
instruct
briefli
equal
volum
room
temperatur
media
renillaglo
reagent
ad
cell
plate
incub
least
min
room
temperatur
luminesc
detect
via
luminesc
detect
use
dtx
multimod
detector
beckman
coulter
percent
luminesc
calcul
rel
dmso
control
rapamycin
obtain
lc
laboratori
cat
erk
inhibitor
obtain
medchem
express
cat
inhibitor
selleckchem
cat
inhibitor
purchas
medchem
express
cat
inhibitor
emdmillipor
cat
cell
treat
h
dmso
inhibitor
choic
given
experi
pretreat
drug
remov
cell
infect
h
wash
viru
inoculum
cell
cultur
complet
media
drug
cell
collect
respect
assay
time
point
statist
analys
unpair
twotail
student
ttest
extra
sumofsquar
f
test
perform
use
graphpad
prism
softwar
version
la
jolla
ca
usa
inhibitor
alon
combin
inhibitor
decreas
rvfv
replic
vitro
capabl
activ
ribosom
protein
phosphoryl
ser
thu
facilit
translat
activ
therefor
inhibitor
target
either
alon
combin
evalu
determin
influenc
rvfv
replic
mous
hepatocyt
chose
inhibitor
analysi
compound
inhibit
activ
high
specif
cell
cytotox
cc
effect
concentr
ec
assay
perform
rule
mous
hepatocyt
cell
toxic
determin
appropri
dose
use
vitro
efficaci
studi
balbc
hepatocyt
somewhat
toler
inhibitor
cc
figur
tabl
display
ec
rvfv
figur
tabl
analysi
cell
signal
protein
demonstr
increas
phosphoryl
thr
downstream
protein
ribosom
protein
ser
ser
follow
rvfv
infect
agreement
previou
result
figur
compar
lane
lane
treatment
result
decreas
phosphoryl
ribosom
protein
ser
thr
ser
figur
lane
decreas
phosphoryl
surpris
given
autophosphoryl
site
rather
phosphoryl
mtor
addit
level
rvfv
np
decreas
follow
treatment
figur
lane
consist
inhibit
viral
translat
reduct
viral
titer
also
observ
although
statist
signific
figur
data
confirm
inhibit
suppress
rvfv
replic
inhibitor
use
chemotherapi
studi
show
specif
inhibit
activ
therefor
use
drug
inhibit
context
rvfv
infect
cell
toler
treatment
decreas
viabil
observ
highest
concentr
test
figur
contrast
attempt
determin
ec
inhibitor
shown
drug
concentr
increas
viral
replic
increas
well
figur
inhibit
phosphoryl
ribosom
protein
well
decreas
follow
drug
treatment
mock
infect
sampl
figur
lane
surprisingli
drug
treatment
context
infect
result
appar
chang
phosphoryl
ribosom
protein
modestli
increas
amount
rvfv
np
figur
lane
level
infecti
viral
titer
increas
approxim
log
drug
concentr
test
figur
result
indic
infect
cell
resist
inhibit
andor
inhibitor
viral
agonist
antagonist
relat
infect
mous
hepatocyt
kinas
inhibitor
chemotherapi
treatment
use
alon
combin
want
determin
synergist
effect
could
achiev
use
two
kinas
inhibitor
simultan
rvfv
infect
cell
even
though
result
viral
replic
aim
determin
inhibitor
combin
could
mitig
kinas
redund
term
ribosom
protein
phosphoryl
result
global
shutdown
phosphoryl
lead
decreas
rvfv
protein
product
replic
cc
ec
assay
perform
combin
treatment
like
combin
two
inhibitor
would
less
toler
singl
treatment
regimen
cell
viabil
greatli
affect
drug
combin
inhibitor
inhibitor
calcul
cc
figur
tabl
inhibitor
combin
effect
suppress
rvfv
inhibit
observ
figur
wherea
either
treatment
alon
inhibit
rvfv
concentr
figur
protein
phosphoryl
figur
infecti
titer
figur
evalu
presenc
drug
concentr
minim
effect
cell
viabil
phosphoryl
ribosom
protein
decreas
follow
drug
treatment
figur
lane
addit
level
rvfv
np
rvfv
titer
figur
significantli
decreas
result
demonstr
use
kinas
inhibitor
combin
inhibitor
result
signific
decreas
rvfv
replic
viral
protein
product
explor
kinas
involv
regul
translat
pathway
evalu
import
mapk
erk
influenc
phosphoryl
end
mapk
inhibitor
erk
inhibitor
evalu
first
identifi
mapk
inhibitor
prevent
mapk
activ
competit
bind
atp
pocket
bind
inhibit
mek
prevent
phosphoryl
activ
erk
cell
toler
mapk
inhibitor
appreci
cell
toxic
observ
even
figur
likewis
decreas
cell
viabil
observ
highest
concentr
erk
inhibitor
test
figur
inhibit
rvfv
nt
potent
rvfv
even
result
inhibit
figur
inhibit
figur
respect
inhibit
mapk
result
minim
reduct
wherea
inhibit
erk
result
appreci
decreas
phosphoryl
figur
addit
inhibit
mapk
erk
result
minim
inhibit
ribosom
protein
phosphoryl
rvfv
np
level
viral
titer
figur
figur
result
demonstr
mapk
inhibitor
erk
inhibitor
limit
effect
rvfv
replic
use
alon
order
build
success
use
fda
approv
drug
rapamycin
inhibit
rvfv
pathogenesi
sought
use
kinas
inhibitor
combin
rapamycin
interest
identifi
combin
compound
might
ultim
allow
anim
complet
protect
rvfv
pathogenesi
compar
partial
protect
observ
rapamycin
treatment
alon
due
rel
nontox
natur
decreas
trend
viral
replic
note
inhibitor
next
step
determin
combin
rapamycin
would
result
improv
rapamycin
antivir
activ
cell
surprisingli
toler
drug
combin
rapamycin
plu
mapk
inhibitor
display
cc
well
erk
inhibitor
plu
rapamycin
cc
figur
tabl
robust
inhibit
rvfv
observ
combin
treatment
inhibit
lowest
concentr
test
figur
mark
improv
inhibit
observ
figur
figur
rapamycin
alon
figur
effect
combin
two
inhibitor
mere
addit
case
dramat
decreas
replic
would
seen
statist
analysi
curv
confirm
differ
rapamycin
treatment
alon
pvalu
phosphoryl
ribosom
protein
rvfv
np
level
markedli
decreas
inhibitor
combin
figur
b
rapamycin
treatment
alon
figur
addit
signific
reduct
rvfv
titer
observ
even
observ
rapamycin
treatment
alon
figur
result
demonstr
combin
rapamycin
mapk
inhibitor
erk
inhibitor
result
robust
inhibit
rvfv
replic
decreas
viral
protein
product
spite
mani
year
research
antivir
drug
virus
outsid
hiv
influenza
hepat
virus
effect
antivir
treatment
tradit
antivir
focus
target
viral
protein
thu
protein
specif
viru
howev
rna
virus
inher
errorpron
often
quickli
mutat
presenc
drug
target
viral
protein
viral
enzym
base
lab
focus
host
base
protein
therapeut
target
like
harder
virus
develop
escap
mutat
approach
shi
away
past
due
toxic
natur
drug
aim
normal
cellular
process
need
homeostasi
howev
mani
type
drug
use
often
success
slow
stop
progress
cancer
virus
invad
cell
turn
onoff
cellular
pathway
make
progeni
cancer
cell
similar
way
activ
inhibit
cellular
pathway
result
uncheck
cellular
prolifer
potenti
benefit
use
kinas
inhibitor
acut
viral
infect
would
short
durat
use
chemotherapi
drug
use
cancer
often
use
month
time
use
drug
acut
viral
infect
would
need
day
week
durat
achiev
therapeut
effect
greatli
reduc
toxic
effect
drug
bodi
current
studi
focus
kinas
translat
pathway
leverag
point
fight
rvfv
figur
previou
set
experi
note
robust
phosphoryl
downstream
protein
pathway
ribosom
protein
inhibit
rapamycin
treatment
suppress
rvfv
vitro
prevent
rvfv
induc
pathogenesi
current
studi
expand
analysi
kinas
regul
translat
includ
erk
mapk
interest
particular
also
capabl
phosphoryl
ribosom
protein
key
player
translat
multidomain
kinas
two
nonident
function
kinas
domain
consist
amino
acid
linker
region
carboxytermin
dock
site
sever
import
activ
site
includ
phosphoryl
site
follow
variou
growth
signal
serum
stimul
oncogen
perturb
hormon
stimuli
action
erk
kinas
growth
signal
activ
erk
dock
c
termin
dock
domain
phosphoryl
activ
loop
ctermin
kinas
domain
ctkd
follow
autophosphoryl
locat
within
hydrophob
motif
linker
region
follow
potenti
phosphoryl
erk
linker
region
phosphoryl
dock
phosphoryl
ntermin
kinas
domain
ntkd
lead
full
activ
activ
follow
phosphoryl
downstream
substrat
ribosom
protein
interestingli
inhibit
specif
inhibitor
saw
slight
statist
signific
increas
viral
replic
result
suggest
rvfv
hijack
pathway
facilit
replic
addit
inhibit
rvfv
cell
result
signific
reduct
ribosom
protein
phosphoryl
mock
infect
cell
inhibitor
treatment
suppress
phosphoryl
event
possibl
modifi
way
follow
rvfv
infect
make
resist
inhibit
altern
explan
increas
phosphoryl
subsequ
activ
rvfv
infect
cell
compens
loss
activ
result
minim
effect
ribosom
phosphoryl
figur
schemat
depict
influenc
kinas
inhibitor
rvfv
replic
rvfv
infect
lead
induct
erk
mapk
phosphoryl
follow
phosphoryl
phosphoryl
induc
via
mtor
activ
wherea
phosphoryl
erk
andor
indirectli
mapk
phosphoryl
ribosom
protein
lead
increas
mrna
translat
number
kinas
inhibitor
refer
manuscript
figur
number
inhibit
data
present
influenc
differ
kinas
inhibitor
rvfv
replic
test
alon
combin
summar
right
side
diagram
ns
signific
chang
rvfv
titer
previou
work
popova
et
al
demonstr
inhibit
mapk
caus
signific
increas
rvfv
replic
inhibit
erk
kinas
caus
decreas
rvfv
replic
studi
partial
agreement
result
present
within
observ
moder
decreas
rvfv
replic
presenc
mapk
erk
inhibitor
human
small
airway
epitheli
cell
hsaec
use
previou
studi
wherea
studi
pathway
studi
mous
hepatocyt
may
explain
observ
differ
addit
test
erk
maprk
inhibitor
also
includ
use
lack
viral
protein
nss
howev
data
demonstr
similar
reduct
rvfv
replic
erk
mapk
inhibitor
presenc
absenc
nss
result
suggest
nss
influenc
erk
mapk
function
kinas
upstream
induc
phosphoryl
respons
differ
stimuli
erk
often
activ
cellular
environ
growth
differenti
occur
wherea
mapk
activ
time
cellular
stress
result
cellular
environ
lead
apoptosi
phosphoryl
observ
follow
sever
acut
respiratori
syndrom
sar
coronaviru
infect
contrast
observ
noninfect
cell
phosphoryl
respons
sar
coronaviru
infect
depend
phosphoryl
event
import
erk
stimul
activ
rather
phosphoryl
depend
mapk
activ
treatment
mapk
inhibitor
prevent
phosphoryl
event
phosphoryl
rvfv
infect
cell
sensit
erk
inhibit
mapk
inhibit
suggest
phosphoryl
event
follow
classic
form
regul
inhibit
erk
mapk
rvfv
infect
cell
result
signific
inhibit
ribosom
protein
compar
kinas
inhibit
data
suggest
inhibit
erk
mapk
minim
effect
translat
possibl
due
larg
redund
pathway
import
compon
current
studi
combin
use
inhibitor
suppress
viral
replic
cell
treat
erk
inhibitor
mapk
inhibitor
togeth
rapamycin
fda
approv
drug
demonstr
efficaci
rvfv
signific
decreas
viral
replic
observ
figur
likewis
signific
decreas
viral
replic
seen
cell
treat
inhibitor
inhibitor
figur
case
combin
inhibitor
result
largest
suppress
viral
replic
compar
inhibitor
use
isol
also
result
largest
suppress
translat
signal
suggest
potent
shutdown
signal
pathway
need
suppress
rvfv
replic
data
indic
target
multipl
key
kinas
within
translat
pathway
allow
robust
viral
inhibit
caveat
studi
analyz
viral
replic
use
report
viru
lack
viral
protein
nss
rvfv
addit
wildtyp
rvfv
contain
nss
nss
main
rvfv
virul
factor
respons
suppress
interferon
multipl
mechan
includ
induc
degrad
pkr
tfiih
therefor
would
expect
greater
viral
inhibit
follow
inhibitor
treatment
may
observ
absenc
nss
cell
abl
mount
effect
antivir
respons
inde
observ
greater
inhibit
rvfv
replic
absenc
nss
inhibitor
treatment
compar
presenc
nss
figur
howev
inhibitor
treatment
either
alon
combin
display
similar
inhibit
presenc
absenc
ns
given
import
translat
pathway
would
interest
determin
sensit
virus
kinas
inhibitor
analysi
would
enabl
greater
understand
kinas
requir
virus
differ
famili
think
inhibit
translat
least
part
respons
posit
antivir
effect
drug
fulli
acknowledg
like
part
stori
exampl
erk
mapk
involv
mani
cellular
event
induc
cell
cycl
regul
cell
surviv
transcript
innat
immun
respons
futur
work
focus
molecular
mechan
behind
benefici
aspect
drug
need
one
overarch
goal
find
safe
effect
antivir
drug
end
current
focus
hostbas
therapeut
worldwid
effect
antivir
therapi
date
look
problem
anew
hope
find
novel
way
fight
deadli
viral
infect
current
strategi
inhibit
machineri
need
virus
propag
case
depriv
form
translat
shutoff
kinas
inhibitor
studi
establish
combin
therapi
effect
slow
viral
replic
done
lower
drug
concentr
necessari
individu
drug
therapi
